Clearside Biomedical Inc
NASDAQ:CLSD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shentong Robot Education Group Co Ltd
HKEX:8206
|
HK |
|
J
|
Jiangnan Mould & Plastic Technology Co Ltd
SZSE:000700
|
CN |
|
H
|
Honasa Consumer Ltd
NSE:HONASA
|
IN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (10.1), the stock would be worth $12.3 (2 900% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.3 | $0.41 |
0%
|
| Industry Average | 10.1 | $12.3 |
+2 900%
|
| Country Average | 14.4 | $17.52 |
+4 174%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$-4.7m
|
/ |
Jul 2025
$-21.5m
|
= |
|
|
$-4.7m
|
/ |
Dec 2025
$-17.7m
|
= |
|
|
$-4.7m
|
/ |
Dec 2026
$-7.4m
|
= |
|
|
$-4.7m
|
/ |
Dec 2027
$-11m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Clearside Biomedical Inc
NASDAQ:CLSD
|
2.1m USD | 0.3 | -0.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 28.5 | 42.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 16.9 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.7 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 16.5 | 29.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 9.9 | 15.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 12.5 | 20.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.3 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 7.7 | 20.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 7.1 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Clearside Biomedical Inc
Glance View
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
